Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
ARS

An annual report to security holders

 View HTML
0001558370-24-005799.pdf
0001558370-24-005799.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-24-006451.pdf
0001558370-24-006451.rtf
0001558370-24-006451.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001950047-24-003314.pdf
0001950047-24-003314.rtf
0001950047-24-003314.xls
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001950047-24-003316.pdf
0001950047-24-003316.rtf
0001950047-24-003316.xls
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-24-006563.pdf
0001558370-24-006563.rtf
0001558370-24-006563.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA